Gan&Lee Pharmaceuticals (603087) announced that the company's GZR4 insulin weekly formulation has successfully completed the first subject dose in Phase III clinical trial in China.

GZR4 is an ultra-long-acting insulin injected subcutaneously once a week, suitable for patients with diabetes. Compared with the existing long-acting basal insulin on the market, GZR4 has a longer half-life and lower dosing frequency, can provide more stable blood drug concentration and efficacy, and reduce the risk of hypoglycemia.

As of September 30, 2024, the company has invested a total of RMB 153 million in research and development expenses in the GZR4 project. The project was approved for clinical trials by the China National Medical Products Administration in July 2022, and the first subject dosed in Phase II clinical trials in September 2023. The completion of the first dose in Phase III clinical trials marks another important progress in the GZR4 project, reflecting the company's continued efforts in new drug research and development.

In the first three quarters of 2024, Gan&Lee Pharmaceutical achieved revenue of 2.245 billion yuan and net profit attributable to shareholders of the parent company of 507 million yuan.

https://finance.eastmoney.com/a/202502173321111980.html